Cholesterol-lowering drug for calcium buildup in heart valve
Part of Heart & circulation clinical trials.
This trial tests a drug called a PCSK9 inhibitor, which lowers cholesterol. It may slow down the buildup of calcium in the aortic valve, which can narrow the valve and make it harder for blood to flow. The drug is given as an injection, and you would receive it for 24 months.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 85 years old.
- You have mild or moderate aortic valve narrowing due to calcium buildup, but you do not need valve surgery yet.
- Your LDL (bad) cholesterol is between 2.6 and 4.9 mmol/L, or your Lp(a) (a type of fat) is elevated, or you are already taking a statin for high cholesterol.
- You have not previously taken a PCSK9 inhibitor.
- You are able to take this medication for 2 years and are willing to attend follow-up visits.
- You do not have certain health conditions like severe kidney or liver disease, active cancer, or a recent stroke.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether adding PCSK9 inhibitor injections (to statin treatment) can slow or improve calcific aortic valve stenosis, a condition where the heart’s aortic valve becomes stiff and narrowed. It’s aimed at adults with mild-to-moderate disease or certain people with severe disease but no symptoms.
This trial tests whether a newer cholesterol-lowering medicine can slow down the narrowing of the heart's main valve in people with aortic stenosis. If you qualify, you may be able to take this medicine to potentially delay the need for surgery.
This trial tests if the drug vericiguat can slow down the buildup of calcium in the aortic valve, which causes it to narrow and stiffen. If you have mild-to-moderate aortic valve stenosis and meet the other criteria, this study may help protect your valve from getting worse.
This study tests whether a new injectable cholesterol-lowering drug (called a PCSK9 inhibitor) can help prevent further heart problems by making plaque in your arteries more stable and less likely to cause blocked vessels. It is for people who recently had a heart attack or unstable angina and already received a stent in the blocked artery.
This trial tests a new pill, ataciguat, to slow down the progression of moderate calcific aortic valve stenosis (a condition where your aortic valve stiffens). If you have moderate valve narrowing and meet the other criteria, participation could help find a way to delay needing surgery.
This trial tests whether adding a PCSK9 inhibitor to a statin is better than a statin alone for people with mild-to-moderate narrowing of the carotid artery (the main artery in the neck). It looks at how well these treatments slow plaque buildup and prevent strokes.
Hear when a new Aortic Stenosis, Calcific trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.